ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag grant review disease medicine

bacteria and DNA molecules on a purple background.
Engineering the Microbiome: CRISPR Leads the Way
Mariella Bodemeier Loayza Careaga, PhD | Mar 15, 2024 | 10+ min read
Scientists have genetically modified isolated microbes for decades. Now, using CRISPR, they intend to target entire microbiomes.
Review of Grant Applications
Edith Rosenberg | Aug 20, 1995 | 8 min read
One of the few things that most Americans still believe is that we have the best biomedical research system in the world and that the National Institutes of Health is its indispensable heart. NIH has a dual function: to support basic research in relevant sciences and to support research designed to apply scientific data equitably to improve the health of all United States residents. These two functions are fundamentally different. Basic biomedical research can be, and always should be, as rigo
Capsule Reviews
Bob Grant | Mar 1, 2011 | 4 min read
By Bob Grant Capsule Reviews Asleep: The Forgotten Epidemic That Remains One of Medicine’s Greatest Mysteries by Molly Caldwell Crosby Berkley Publishing Group (March 2010, in paperback February 1, 2011)In Asleep, science writer Molly Caldwell Crosby awakens the specter of a rapacious disease that killed more than one million people all over the world in the 1920s. Encephalitis lethargica, or sleeping sickness, emerged from the ashes of World War I to
Capsule Reviews
Bob Grant | Aug 1, 2014 | 3 min read
The Myth of Mirror Neurons, Curious, Shadow Medicine, and Doctored
Reviewing Peer Review
Ted Agres(tagres@the-scientist.com) | Nov 20, 2005 | 4 min read
Tired of waiting for the National Institutes of Health to approve your grant proposal?
Capsule Reviews
Bob Grant | Feb 28, 2011 | 3 min read
Asleep, The Restless Plant, Genetics of Original Sin, Disease Maps
Week in Review: March 21–25
Tracy Vence | Mar 24, 2016 | 1 min read
Smallest genome yet; MERS-CoV in Kenya; FDA approves new Zika diagnostic; matching private funders with unfunded NIH grant applications; monitoring mRNA with CRISPR
Updated
Merck research facility in San Francisco
Antiviral Pill Lowers Risks of COVID-19 Hospitalization, Death
Chloe Tenn | Oct 1, 2021 | 3 min read
Merck reports that its antiviral molnupiravir was effective against early stages of COVID-19 in high-risk patients in a Phase 3 clinical trial.

Run a Search

ADVERTISEMENT